COMPUTERIZED DYNAMIC POSTUROGRAPHY

Guideline Number: MMG025.E  
Effective Date: May 1, 2017

Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>INSTRUCTIONS FOR USE</td>
<td>1</td>
</tr>
<tr>
<td>BENEFIT CONSIDERATIONS</td>
<td>1</td>
</tr>
<tr>
<td>COVERAGE RATIONALE</td>
<td>1</td>
</tr>
<tr>
<td>APPLICABLE CODES</td>
<td>2</td>
</tr>
<tr>
<td>DESCRIPTION OF SERVICES</td>
<td>2</td>
</tr>
<tr>
<td>CLINICAL EVIDENCE</td>
<td>2</td>
</tr>
<tr>
<td>U.S. FOOD AND DRUG ADMINISTRATION</td>
<td>3</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>3</td>
</tr>
<tr>
<td>GUIDELINE HISTORY/REVISION INFORMATION</td>
<td>4</td>
</tr>
</tbody>
</table>

INSTRUCTIONS FOR USE

This Medical Management Guideline provides assistance in interpreting UnitedHealthcare benefit plans. When deciding coverage, the member specific benefit plan document must be referenced. The terms of the member specific benefit plan document [e.g., Evidence of Coverage (EOC) and Schedule of Benefits (SOB)] may differ greatly from the standard benefit plan upon which this Medical Management Guideline is based. In the event of a conflict, the member specific benefit plan document supersedes this Medical Management Guideline. All reviewers must first identify member eligibility, any federal or state regulatory requirements, and the member specific benefit plan coverage prior to use of this Medical Management Guideline. Other Policies and Guidelines may apply. UnitedHealthcare reserves the right, in its sole discretion, to modify its Policies and Guidelines as necessary. This Medical Management Guideline is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Member benefit coverage and limitations may vary based on the member’s benefit plan Health Plan coverage provided by or through UnitedHealthcare of California, UnitedHealthcare Benefits Plan of California, UnitedHealthcare of Oklahoma, Inc., UnitedHealthcare of Oregon, Inc., UnitedHealthcare Benefits of Texas, Inc., or UnitedHealthcare of Washington, Inc.

BENEFIT CONSIDERATIONS

Essential Health Benefits for Individual and Small Group

For plan years beginning on or after January 1, 2014, the Affordable Care Act of 2010 (ACA) requires fully insured non-grandfathered individual and small group plans (inside and outside of Exchanges) to provide coverage for ten categories of Essential Health Benefits (“EHBs”). Large group plans (both self-funded and fully insured), and small group ASO plans, are not subject to the requirement to offer coverage for EHBs. However, if such plans choose to provide coverage for benefits which are deemed EHBs, the ACA requires all dollar limits on those benefits to be removed on all Grandfathered and Non-Grandfathered plans. The determination of which benefits constitute EHBs is made on a state by state basis. As such, when using this guideline, it is important to refer to the member specific benefit plan document to determine benefit coverage.

COVERAGE RATIONALE

Computerized dynamic posturography (CDP) testing, also called balance board testing or equilibrium platform testing (EPT) is unproven and not medically necessary for evaluating any condition including but not limited to balance disorders.

Overall, there is weak evidence in the peer-reviewed literature regarding the efficacy of CDP for evaluating vestibular and other disorders. There is a lack of well-designed, randomized controlled trials (RCTs) with blinded assessments to
demonstrate the diagnostic utility of CDP compared with standard tests. Furthermore, there is insufficient evidence demonstrating consistent and beneficial effects of CDP testing on patient-relevant outcomes. Therefore, CDP is considered unproven and not medically necessary.

APPLICABLE CODES

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this guideline does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>92548</td>
<td>Computerized dynamic posturography</td>
</tr>
</tbody>
</table>

DESCRIPTION OF SERVICES

Computerized dynamic posturography (CDP), also known as moving platform posturography or dynamic posturography, uses a platform device for evaluating a patient’s ability to maintain balance. CDP has been used to measure a patient's ability to maintain balance under varying conditions when the usual cues that one relies upon to remain upright, vision, proprioception, and vestibular function, are manipulated. The goal of testing is to isolate vestibular symptoms to a specific cause that can often be treated.

Standard diagnostic tests include electronystagmography and rotational chair tests, which evaluate eye movements in response to a number of different stimuli including the position and rotation of the head.

CLINICAL EVIDENCE

The evidence in the published peer-reviewed medical literature examining the safety and effectiveness of CDP includes mostly older studies, some poorly designed, with inconsistent results (Morgan, et al., 2002; Di Fabio, 1996; Di Fabio, 1995). Additional evidence evaluating the use of CDP is primarily in the form of prospective and retrospective case series and validation studies with patient populations ranging from 20-216 (Palm et al., 2014; Ebersbach, et al., 2011; Mockford, et al., 2010; Gouveris, et al., 2007; Mbongo, et al., 2005; Sataloff, et al., 2005; Soto, et al., 2004; Artuso, et al., 2004; Amin; et al., 2002). Studies included patients with various disorders including vertigo, vestibular schwannoma, and Ménière’s disease. Overall, small sample sizes and poor study design limit the generalizability of study results. The data does not reliably demonstrate beneficial effects of CDP evaluation on patient outcomes.

A study was conducted by Buster et al. (2016) which compared Computerized Dynamic Posturography (CDP) scores from individuals with traumatic brain injuries (TBI) to controls to determine if CDP could differentiate between the two groups and determine if there was a learning effect associated with testing that could be used to guide evaluation of baseline balance. Ten ambulatory individuals with a history of severe TBI and 10 individuals without participated in three CDP sessions (24-72 hours apart). Participants performed the Berg Balance Test, Dynamic Gait Index and three trials of a standardized balance assessment during each session. Dynamic Movement Analysis (DMA) scores were recorded for each test. Individuals with TBI scored 93% higher (i.e. reflecting poorer balance) than the control group. The group with TBI exhibited 6.6-times more variability compared to the control group. A learning effect was detected in the group with TBI on the first day of testing. The authors concluded that the CDP system detected balance differences between individuals with TBI and controls and given the documented learning effect, the best of three trials should be used to accurately assess baseline scores. The significance of this study is limited by small sample size and short follow-up period.

Smoot et al (2015) conducted a feasibility study with ten children; five with autism spectrum disorder (ASD) and five with typical development (TD) using posturography to monitor changes following vestibular input. Each child participated in a 10 min vestibular swing activity with pre- and post-intervention evaluations under four different sensory testing conditions. Sway ranges, mean sway velocity, sway root mean square (RMS), and sample entropy were calculated from center of pressure (COP) data. All five children with ASD demonstrated decreased mean sway velocity in the eyes open/flat plate condition post-intervention. Four of the five children with ASD demonstrated an increase in RMS and a decrease in anterior/posterior sample entropy post-intervention in the eyes closed, foam pad condition and eyes open, flat plate condition respectively. The authors concluded that using posturography with sensory integration warrants further investigation. This is an uncontrolled study with a small sample size.

Due to limited studies, small sample sizes, and weak study designs, there is insufficient evidence to conclude that CDP is useful for evaluating any condition. Further clinical trials demonstrating the clinical usefulness of CDP are needed.
Professional Societies

American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS)

AAO-HNS recognizes that the following tests or treatments are medically indicated and appropriate in the evaluation or treatment of persons with suspected balance or dizziness disorders:

- Static platform posturography
- Computerized static platform posturography
- Computerized dynamic platform posturography
- Dynamic (or moving) platform posturography

U.S. FOOD AND DRUG ADMINISTRATION (FDA)

Devices for testing vestibular dysfunction are captured in the FDA 510(k) database under Product Code LXV (Vestibular Analysis Apparatus), IKN (Electromyograph, Diagnostic) and/or Product Code KHX (Force-Measuring Platforms). Note that devices in product categories LXV and KHX are Class I, 510(k) exempt devices. Devices in product category IKN are class II devices which are also 510(k) exempt. Although many manufacturers have voluntarily submitted product information via the 510(k) process, it is not a requirement. All manufacturers are, however, required to register their establishment and submit a “Device Listing” form; these records can be viewed in the Device Listing Database. See the following Web sites for more information:

http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm
(Accessed March 1, 2017)

REFERENCES

American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) [Internet]; Posturography position statement; Revised September 20, 2014

Amin M, Girardi M, Konrad HR, et al; A comparison of electronystagmography results with posturography findings from the BalanceTrak 500; Otol Neurotol; 2002 Jul; 23 (4): 488-93

Artuso A, Garozzo A, Contucci AM, et al; Role of dynamic posturography (Equitest) in the identification of feigned balance disturbances; Acta Otorhinolaryngol Ital; 2004 Feb; 24 (1): 8-12


Di Fabio RP; Meta-analysis of the sensitivity and specificity of platform posturography; Arch Otolaryngol Head Neck Surg; 1996; 122 (2): 150-156

Di Fabio RP; Sensitivity and specificity of platform posturography for identifying patients with vestibular dysfunction; Phys Ther; 1995 Apr; 75 (4): 290-305

Ebersbach G, Gunkel M; Posturography reflects clinical imbalance in Parkinson's disease; Mov Disord; 2011 Feb 1; 26 (2): 241-6


Mockford KA, Mazari FA, Jordan AR, et al; Computerized Dynamic Posturography in the Objective Assessment of Balance in Patients with Intermittent Claudication; Ann Vasc Surg; 2011 Feb; 25 (2): 182-90

Morgan SS, Beck WG, Dobie RA; Can posturography identify informed malingerers?; Otol Neurotol; 2002 Mar; 23 (2): 214-7

National Institute on Deafness and Other Communication Disorders (NIDCD) [Internet]; Balance disorders; January 2000; Updated April 2014


Sataloff RT, Hawkshaw MJ, Mandel H, et al; Abnormal computerized dynamic posturography findings in dizzy patients with normal ENG results; Ear Nose Throat J; 2005 Apr; 84 (4): 212-4


GUIDELINE HISTORY/REVISION INFORMATION

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
</table>
| 05/01/2017 | • Updated supporting information to reflect the most current clinical evidence, FDA information and references; no change to coverage rationale or list of applicable codes  
|          | • Archived previous policy version MMG025.D                                          |